Neuphoria Therapeutics Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Neuphoria Therapeutics is in Stage 4, the downtrend phase, now in week 2 (since Oct 13, 2026). It closed at $3.48, 44.2% below its 52-week high and below its 200-day average, which is falling.

$3.48

+0.00% today

$18.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NEUP early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 55w

S1 16w

S2 27w

S1 16w

S4 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 8w → S1 3w → S2 6w → S3 1w → S4 55w → S1 16w → S2 27w → S3 5w → S4 12w → S1 16w → S4 14w → S1 1w → S4 1w current

Total tracked: 165 weeks across 13 stage runs.

NEUP among Biotechnology280th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…280	NEUPNeuphoria Therapeutics Inc.	Stage 4 · wk 2	34	−5.4%

vs 52W High

-44.2%

$3.24 lo$6.24 hi

44.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-16.9%

200 DMA: $4.19 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.16x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-5.4%

-4.4%

-29.1%

YTD

-8.9%

-28.2%

Scan Membership

Breakout Watch

Latest: 2025-05-05

2 appearances in last 60 days. First seen: 2023-11-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.16x

2026-10-21S4

Wk 2 · Vol 0.24x

2026-10-20S4

Wk 2 · Vol 0.67x

2026-10-19S4

Wk 1 · Vol 1.31x

2026-10-16S4

Wk 1 · Vol 2.59x

2026-10-15S4

Wk 1 · Vol 0.63x

2026-10-14S4

Wk 1 · Vol 1.48x

2026-10-13S41→4

Wk 1 · Vol 0.88x

2026-10-12S1

Wk 1 · Vol 0.32x

2026-10-09S1

Wk 1 · Vol 0.08x

2026-10-08S1

Wk 1 · Vol 0.49x

2026-10-07S14→1

Wk 1 · Vol 0.13x

Moving averages & range

50 DMA

$3.65

200 DMA

$4.19

52W High

$6.24

52W Low

$3.24

5D Low

$3.30

Resistance levels (recent highs)

20d High

$3.65

60d High

$3.98

120d High

$5.48

250d High

$6.24

Next resistance

+4.9%

to 20d High

ROE

-61.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.8

Neuphoria Therapeutics: quick answers

What stage is Neuphoria Therapeutics in?

As of Oct 22, 2026, Neuphoria Therapeutics (NEUP) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 13, 2026 and is in week 2. What the four stages mean

Is Neuphoria Therapeutics in an uptrend?

No. Neuphoria Therapeutics is in a Stage 4 downtrend. It trades 16.9% below its 200-day average, which is falling.

How far is Neuphoria Therapeutics from its 52-week high?

Neuphoria Therapeutics closed at $3.48 on Oct 22, 2026, 44.2% below its 52-week high of $6.24. Its 52-week low is $3.24.

How has Neuphoria Therapeutics performed over the past year?

As of Oct 22, 2026, Neuphoria Therapeutics is down 28.2% over the past year and down 8.9% so far in 2026.

Which sector and industry is Neuphoria Therapeutics in?

Neuphoria Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.